Tech Transfer Roundup: Deerfield, Broad Institute Alliance Selects Two Cancer Programs
An alliance of Deerfield and the Broad Institute to accelerate research into high-mortality diseases identifies its first two research projects, while Janssen and UPenn look into gene therapy for Alzheimer's disease.
You may also be interested in...
Investor Deerfield Management and genomic sequencing giant Illumina entered into a five-year partnership to identify novel targets and drug candidates that may be spun out into new companies.
Vanderbilt launches new biotech with Deerfield aimed at reworking the drug development paradigm, while also expanding its cancer research work with BI. Grunenthal partners with Katholieke Universiteit Leuven to investigate ion channel modulation approaches in pain.
J.P. Morgan Notebook Day 2: Walmsley On Diversity, Amgen's Overseas Cash, Growing Opdivo, Mylan On US Generic Pricing, Boston's Pipeline And J&J In Alzheimer's
Daily round-up of news and notes from the 2018 J.P. Morgan Healthcare Conference in San Francisco: GSK's Walmsley looks to be a leader on diversity, Amgen talks tax reform and deals, Mylan raises the issue of generic drug shortages, Boston builds out its pipeline, and J&J is dealing in Alzheimer's disease.